Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

The most significant recent development for SpringWorks is the agreement by Merck KGaA to acquire the company at $47 per share. This deal values SpringWorks at approximately $3.9 billion in equity ...

Barron’s has long favored dividend-paying stocks for those seeking income. But bonds now deserve a hard look because they are ...

China's biotech sector is rapidly advancing due to heavy R&D investment and a push for technological self-sufficiency. See ...

The Grignard Reagents market is witnessing steady demand across pharmaceuticals, agrochemicals, and chemical synthesis due to their versatility in or ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD stock is a strong buy.

Market Cap: $198.3 B Merck & Company Inc (MRK) is a global health care company that delivers innovative health solutions through medicines, vaccines, biologic therapies and animal health products.

Transformation in healthcare is ongoing and purpose-driven. It’s not a fleeting trend but a continuous process rooted in ...

SAN DIEGO, CA, UNITED STATES, July 2, 2025 /EINPresswire.com/ -- Stellar Market Research examines the growth rate of the Veterinary Pain Management Market during the forecasted period 2025-2032 The ...